EMCURE PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of EMCURE PHARMACEUTICALS have increased by 11.23% YoY .
The Earnings Per Share (EPS) of EMCURE PHARMACEUTICALS has decreased by -6.53 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
EMCURE PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 544210|NSE : EMCURE]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹6,658 Cr | ₹5,986 Cr | ₹5,855 Cr | ₹6,056 Cr | ₹5,049 Cr |
| Expenses | ₹5,429 Cr | ₹4,805 Cr | ₹4,525 Cr | ₹4,824 Cr | ₹4,345 Cr |
| Operating Profit (Excl OI) | ₹1,230 Cr | ₹1,181 Cr | ₹1,330 Cr | ₹1,232 Cr | ₹704 Cr |
| Other Income | ₹57 Cr | ₹46 Cr | ₹63 Cr | ₹35 Cr | ₹82 Cr |
| Interest | ₹237 Cr | ₹214 Cr | ₹176 Cr | ₹198 Cr | ₹257 Cr |
| Depreciation | ₹312 Cr | ₹260 Cr | ₹245 Cr | ₹323 Cr | ₹321 Cr |
| Profit Before Tax | ₹727 Cr | ₹747 Cr | ₹973 Cr | ₹657 Cr | ₹105 Cr |
| Profit After Tax | ₹528 Cr | ₹562 Cr | ₹703 Cr | ₹419 Cr | ₹101 Cr |
| Consolidated Net Profit | ₹498 Cr | ₹532 Cr | ₹662 Cr | ₹392 Cr | ₹84 Cr |
| Earnings Per Share (Rs) | ₹27.50 | ₹29.42 | ₹36.62 | ₹21.68 | ₹4.62 |
| PAT Margin (%) | 7.77 | 9.21 | 11.75 | 6.70 | 1.93 |
| ROE(%) | 19.45 | 25.21 | 33.19 | 20.19 | 5.43 |
| ROCE(%) | 19.87 | 21.97 | 26.56 | 19.75 | 9.00 |
| Total Debt/Equity(x) | 0.71 | 0.88 | 1.05 | 1.02 | 1.15 |
Key Financials |
||
| Market Cap | : | ₹ 25,681.0 Cr |
| Revenue (TTM) | : | ₹ 7,896.0 Cr |
| Net Profit(TTM) | : | ₹ 707.5 Cr |
| EPS (TTM) | : | ₹ 37.3 |
| P/E (TTM) | : | 36.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| EMCURE PHARMACEUTICALS | 9% | -0.6% | -4.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.6% | -0.4% | 4.7% |
| DIVIS LABORATORIES | -2.2% | 1.7% | 47.3% |
| CIPLA | -0.2% | -1.4% | -1.9% |
| TORRENT PHARMACEUTICALS | 2.5% | 4.8% | 12.2% |
| DR REDDYS LABORATORIES | -2.6% | -8.1% | -4.9% |
| MANKIND PHARMA | 11.1% | 13.3% | 19.9% |
| ZYDUS LIFESCIENCES | -1.5% | -0.7% | -17% |
| LUPIN | 0.2% | -3.8% | 3.6% |
EMCURE PHARMACEUTICALS Revenues
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 11.23 % |
| 5 Yr CAGR | 7.16 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹6,658 Cr | 11.23 | |
| Mar2023 | ₹5,986 Cr | 2.23 | |
| Mar2022 | ₹5,855 Cr | -3.32 | |
| Mar2021 | ₹6,056 Cr | 19.96 | |
| Mar2020 | ₹5,049 Cr | - | |
EMCURE PHARMACEUTICALS Operating Profit
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 4.11 % |
| 5 Yr CAGR | 14.97 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,230 Cr | 4.11 | |
| Mar2023 | ₹1,181 Cr | -11.18 | |
| Mar2022 | ₹1,330 Cr | 7.95 | |
| Mar2021 | ₹1,232 Cr | 75.01 | |
| Mar2020 | ₹704 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -6.39 % |
| 5 Yr CAGR | 7.29 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 18.47% | -6.39 | |
| Mar2023 | 19.73% | -13.12 | |
| Mar2022 | 22.71% | 11.65 | |
| Mar2021 | 20.34% | 45.91 | |
| Mar2020 | 13.94% | - | |
EMCURE PHARMACEUTICALS Profit After Tax
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | -6.36 % |
| 5 Yr CAGR | 56.24 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹498 Cr | -6.36 | |
| Mar2023 | ₹532 Cr | -19.66 | |
| Mar2022 | ₹662 Cr | 68.87 | |
| Mar2021 | ₹392 Cr | 369.04 | |
| Mar2020 | ₹84 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -15.64 % |
| 5 Yr CAGR | 41.65 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 7.77 % | -15.64 | |
| Mar2023 | 9.21 % | -21.62 | |
| Mar2022 | 11.75 % | 75.37 | |
| Mar2021 | 6.7 % | 247.15 | |
| Mar2020 | 1.93 % | - | |
EMCURE PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | -6.53 % |
| 5 Yr CAGR | 56.20 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹28 | -6.53 | |
| Mar2023 | ₹29 | -19.66 | |
| Mar2022 | ₹37 | 68.91 | |
| Mar2021 | ₹22 | 369.26 | |
| Mar2020 | ₹4.62 | - | |
EMCURE PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | -9.56 % |
| 5 Yr CAGR | 21.90 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 19.87% | -9.56 | |
| Mar2023 | 21.97% | -17.28 | |
| Mar2022 | 26.56% | 34.48 | |
| Mar2021 | 19.75% | 119.44 | |
| Mar2020 | 9% | - | |
EMCURE PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹1,355.2 |
| Current MarketCap | : | ₹ 25,681.0 Cr |
| Updated EOD on | : | Jul 14,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| EMCURE PHARMACEUTICALS | 9% |
-0.6% |
-4.6% |
| SENSEX | -1.4% |
0.7% |
2.4% |
EMCURE PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE IPO | 3.9% | 6.6% | -1.6% |
| BSE 250 SMALLCAP INDEX | 0.5% | 3% | -0.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY IPO INDEX | 2.9% | 4.6% | NA |
| NIFTY SMALLCAP 250 | 0.5% | 3.1% | 0.6% |
| NIFTY 500 EQUAL WEIGHT | 0.1% | 1.9% | -0.1% |
| NIFTY MIDSMALLCAP 400 | -0.3% | 1.9% | 1.5% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -0.5% | 1.7% | 1.4% |
You may also like the below Video Courses
FAQ about EMCURE PHARMACEUTICALS Financials
How the annual revenues of EMCURE PHARMACEUTICALS have changed ?
The Revenues of EMCURE PHARMACEUTICALS have increased by 11.23% YoY .
How the Earnings per Share (EPS) of EMCURE PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of EMCURE PHARMACEUTICALS has decreased by -6.53 % YoY .
Check out Intrinsic Value of Peers of EMCURE PHARMACEUTICALS
Compare Stock Analytics of Peers of EMCURE PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
